Immunomic Therapeutics immunomix.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Immunomic Therapeutics (ITI) is a clinical stage biotechnology company developing vaccines based on LAMP Technology. The company's LAMP-vax platform increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP constructs have been validated in human clinical trials (Geron's GRNVAC1) cancer and have been applied to a wide breadth of targets including allergy, ...Show all

Immunomic Therapeutics (ITI) is a clinical stage biotechnology company developing vaccines based on LAMP Technology. The company's LAMP-vax platform increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall...Show all

Company (Alive / Active)

Phone: 301-968-3501

Fax:

15010 Broschart Road
Suite 250
Rockville, 20850
Maryland, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Immunomic Therapeutics $19.1M Aug 3, 2018
See all 13 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Immunomic Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 10 investors

Competitors

Company Status Description Investors

Aldagen

Israel
AcquiredAldagen, formerly Stemco Biomedical, is a clinical-stage biopharmaceutical company developing regenerative cell therapies.Login to see details

Nps Pharmaceuticals

Bedminster, New Jersey, United States
AcquiredNPS Pharmaceuticals is developing specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and in preclinical development for the GI Mucositis and Necrotizing Enterocolitis indications and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 clinical development as a hormone therapy for hypo...Show allLogin to see details
See all 13 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Nucleic acids for treatment of allergies Mar 02, 2016 Aug 29, 2017 Patent
Nucleic acids for treatment of allergies Jul 31, 2017 Application
Nucleic acids for treatment of peanut allergies Jun 23, 2015 Application